MoonLake upgraded at Rothschild & Co Redburn citing potential FDA nod for lead drug
Rothschild & Co Redburn upgraded MoonLake Immunotherapeutics (MLTX) to Buy from Neutral, citing a “clearer path to approval” for the Swiss biotech’s lead candidate, sonelokimab, targeted at a skin disorder known as hidradenitis suppurativa in the...
Seeking Alpha